GlaxoSmithKline, Centers for Disease Control and Prevention sales and marketing update

The CDC’s Advisory Committee on Immunization Practices (ACIP) issued a Category B recommendation for meningococcal group B vaccination, including GlaxoSmithKline’s Bexsero, in people ages 16-23. A Category B recommendation requires that the decision to vaccinate be made by qualified healthcare professionals based on individual patient risk assessment. The ACIP also voted to include Bexsero in the Vaccines for Children program for patients ages 16-18. ...